Benchmark Upholds Buy Rating on Abbott Laboratories Despite Subdued Q4 Performance
Benchmark has reaffirmed its Buy rating on Abbott Laboratories with a $145 price target, anticipating a 33% rise from current levels. The healthcare giant posted tepid fourth-quarter results, largely due to softness in its Nutrition Products division, but remains hopeful about recovery driven by contract wins and product launches scheduled for 2026…